These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9533004)

  • 41. Cutaneous mucinosis and skin necrosis complicates interferon alfacon-1 (consensus interferon) treatment of chronic hepatitis C.
    Siewert E; Weyers W; Dietrich CG; Geier A; Lammert F; Matern S
    Eur J Med Res; 2005 Feb; 10(2):63-7. PubMed ID: 15817424
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapeutic strategies for hepatitis C].
    Tsubota A; Kumada H
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):441-7. PubMed ID: 15359839
    [No Abstract]   [Full Text] [Related]  

  • 43. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.
    Sjogren MH; Sjogren R; Lyons MF; Ryan M; Santoro J; Smith C; Reddy KR; Bonkovsky H; Huntley B; Faris-Young S
    Dig Dis Sci; 2007 Jun; 52(6):1540-7. PubMed ID: 17406822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C.
    García-Buey L; García-Monzón C; Rodriguez S; Borque MJ; García-Sánchez A; Iglesias R; DeCastro M; Mateos FG; Vicario JL; Balas A
    Gastroenterology; 1995 Jun; 108(6):1770-7. PubMed ID: 7768382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A case report of concomitant vitiligo in a patient treated with interferon alfa-1b for chronic hepatitis B infection].
    Hu MF; Li YL; Zhuang L
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):872. PubMed ID: 21138645
    [No Abstract]   [Full Text] [Related]  

  • 46. [Meno-metrorrhagia. Differential diagnosis and treatment].
    Bjøro K
    Tidsskr Nor Laegeforen; 1979 May; 99(13):648-51. PubMed ID: 451969
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of HCV liver disease by recombinant interferon alpha.
    Bailly F; Si N; Si A; Trepo C
    Nephrol Dial Transplant; 1996; 11 Suppl 4():56-7. PubMed ID: 8918757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is steroid therapy needed in the treatment of destructive thyrotoxicosis induced by alpha-interferon in chronic hepatitis C?
    Minelli R; Valli MA; Di Seclì C; Finardi L; Chiodera P; Bertoni R; Ferrari C; Barilli AL; Coiro V; Saccani Jotti G; Delsignore R
    Horm Res; 2005; 63(4):194-9. PubMed ID: 15860921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis.
    Imagawa A; Itoh N; Hanafusa T; Oda Y; Waguri M; Miyagawa J; Kono N; Kuwajima M; Matsuzawa Y
    J Clin Endocrinol Metab; 1995 Mar; 80(3):922-6. PubMed ID: 7883851
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
    Alaimo G; Di Marco V; Ferraro D; Di Stefano R; Porrovecchio S; D'Angelo F; Calvaruso V; Craxì A; Almasio PL
    World J Gastroenterol; 2006 Nov; 12(42):6861-4. PubMed ID: 17106937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1).
    Hass HG; Klein R; Nehls O; Kaiser S
    J Clin Gastroenterol; 2009; 43(5):470-6. PubMed ID: 19247202
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Therapy of chronic non-A, non-B hepatitis with interferon].
    Hess G
    Fortschr Med; 1991 Jan; 109(2):33-4, 39-40. PubMed ID: 1902813
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response.
    Sethi A; Shiffman ML
    Clin Liver Dis; 2005 Aug; 9(3):453-71, vii-viii. PubMed ID: 16023977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pubertal meno-metrorrhagia].
    Chartier M
    Ann Pediatr (Paris); 1984 Mar; 31(3):209-15. PubMed ID: 6372618
    [No Abstract]   [Full Text] [Related]  

  • 55. Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C.
    Borgia G; Reynaud L; Gentile I; Cerini R; Ciampi R; Dello Russo M; Piazza M
    J Interferon Cytokine Res; 2001 Jul; 21(7):469-70. PubMed ID: 11506739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A case of ventricular tachycardia occurred during interferon therapy in chronic hepatitis C].
    Omae A; Katayama K; Kakiuchi Y; Okada N; Hijioka Y; Nagai Y; Ito Y; Hagiwara H; Kasahara A; Hayashi N
    Nihon Naika Gakkai Zasshi; 1995 Oct; 84(10):1734-5. PubMed ID: 8537730
    [No Abstract]   [Full Text] [Related]  

  • 57. [Severe local cutaneous necrosis during treatment with interferon-alpha and ribavirin for chronic viral hepatitis C].
    de Ledinghen V; Brudieux E; Beylot-Barry M; Belleannee G; Doutre MS; Couzigou P
    Gastroenterol Clin Biol; 1997; 21(6-7):523-4. PubMed ID: 9295983
    [No Abstract]   [Full Text] [Related]  

  • 58. Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C.
    Mitoro A; Yoshikawa M; Yamamoto K; Mimura M; Yoshikawa Y; Shiroi A; Mochi T; Sakamoto T; Yamao J; Kikuchi E
    Intern Med; 1993 Apr; 32(4):327-31. PubMed ID: 8102914
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Long term/intermittent treatment of chronic hepatitis C with recombinant interferon alfa-2b].
    Hakozaki Y; Fujioka T; Katou M; Kondo T; Oba K; Nakagawa K; Shirahama T
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):1001-6. PubMed ID: 7563656
    [No Abstract]   [Full Text] [Related]  

  • 60. Breakthrough of interferon therapy.
    Scalori A; Ricci A; Bellati G; Colloredo G; Roffi L
    Am J Gastroenterol; 1996 Oct; 91(10):2249-50. PubMed ID: 8855768
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.